BRITISH MEDICAL JOURNAL VOLUME 287 10 DECEMBER 1983 Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer Adenocarcinoma of the prostate is androgen dependent in 80°' of patients. Most circulating testosterone is secreted by the testes, but the adrenal glands contribute appreciably towards production of androgens. Conventional endocrine management is currently orientated towards suppressing testicular production of testosterone either directly by orchidectomy or by treatment with oestrogen. Recently superactive analogues of the hypothalamic peptide gonadotrophin releasing hormone have been used to inhibit pituitary secretion of luteinising hormone and thus to suppress gonadal production of testosterone.' As adrenal production of androgens is independent of this axis, patients who relapse while receiving conventional treatment may not have escaped total endocrine control. It follows therefore that suppression of adrenal androgen production might be beneficial.
Ketoconazole is an oral imidazole drug in routine use as a systemic antifungal agent. It has recently been found to block both gonadal and adrenal synthesis of androgens.' We report on two patients with advanced metastatic disease who relapsed despite achieving serum concentrations of testosterone seen after castration but showed early improvement when given ketoconazole. figure) .
Case 2-Adenocarcinoma of the prostate had been diagnosed six years previously in a 72 year old man. Temporary remission had been achieved by bilateral orchidectomy, but in July 1982 a bone scan showed his condition to be deteriorating and his acid phosphatase activity was rising. A temporary symptomatic and clinical response was observed during treatment with an analogue of luteinising hormone releasing hormone,' but in June 1983 progressive disease was again established despite maintained suppression of testosterone concentrations (< 1-0 nmol/l (0-29 ng/ml)). After the addition of ketoconazole to treatment (200 mg four times daily rising to 400 mg four times daily) serum tartrate labile acid phosphatase activity fell (figure).
Comment
Ketoconazole is used routinely as a systemic antifungal agent. Side effects are rare but include mild gastrointestinal disturbances, rashes, and hepatotoxicity.3 The drug's ability to interfere with both gonadal and adrenal synthesis of androgens has only recently been identified.2 Single dose studies have shown effective suppression of testosterone within eight hours and a compensatory rise in serum luteinising hormone concentration.
Relapse after remission induced by endocrine manipulation is a feature of prostatic carcinoma and has been considered to be a result of tumour cells losing their androgen dependency. Adrenal production of androgens, however, has largely been ignored, because the drugs available to suppress it are not well tolerated in high doses. Ketoconazole might, therefore, provide a useful further approach in managing these patients, and indeed a preliminary case has been reported in which ketoconaz le alone was used to treat a prostatic tumour.5 Peripheral suppression of androgen synthesis, however, results in a compensatory rise in gonadotrophins, which may necessitate increasing doses of the drug to maintain suppression against increased pituitary drive. In addition, gonadotrophins are reported to be trophic factors to prostatic tumours. Thus an analogue of luteinising hormone releasing hormone and ketoconazole might be an ideal combination for total inhibition of androgen production. The response of our two patients, who had relapsed despite achieving testosterone concentrations seen after castration, indicates that this novel combined approach to advanced progressive prostatic tumours may be effective.
